Form 4: Recursion Pharma Director Sells Shares Under 10b5-1 Plan

Recursion Pharmaceuticals Director Christopher Gibson reported a series of transactions, including the sale of 40,000 Class A Common Stock under a pre-arranged trading plan.

Summary

• Christopher Gibson, a Director at Recursion Pharmaceuticals, Inc. (RXRX), reported multiple transactions involving Class A Common Stock and Class B Common Stock.
• On February 4, 2026, Gibson converted 40,000 shares of Class B Common Stock into Class A Common Stock and subsequently sold all 40,000 Class A shares at a price of $4.12 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
• On February 6, 2026, Gibson acquired 30,346 shares of Class A Common Stock through the immediate vesting of Restricted Stock Units (RSUs).
• Concurrently, 10,364 shares of Class A Common Stock were withheld by the Issuer at a price of $3.56 per share to cover tax withholding obligations related to the RSU settlement.
• Following these transactions, Gibson directly holds 933,821 shares of Class A Common Stock.
• Gibson also holds significant derivative securities, including 4,583,334 direct Class B Common Stock and various stock options with exercise prices ranging from $2.48 to $11.40, vesting monthly over 48 months.
• Indirect beneficial ownership of Class B Common Stock is held through LAHWRAN-3 LLC (386,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (50,000 shares).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing. The insider sale was pre-planned, and the acquisitions were due to scheduled vesting, which are routine events for corporate directors and do not suggest a significant shift in company outlook.

Positives

• Acquisition of 30,346 Class A Common Stock through RSU vesting, indicating continued equity compensation.
• Conversion of Class B to Class A Common Stock, which can increase liquidity for the holder.

Negatives

• Sale of 40,000 Class A Common Stock, reducing direct ownership.
• Withholding of 10,364 Class A Common Stock for tax obligations, which reduces the net shares received from RSU vesting.

Future Outlook

The filing details future vesting schedules for various stock options, indicating ongoing equity compensation for the director over the next several years, with options expiring between December 2030 and February 2035.

Industry Context

StockSavvy.ai notes that insider sales, especially those executed under a Rule 10b5-1 plan, are common and do not necessarily signal a negative outlook on the company. Such plans are often established well in advance to allow insiders to diversify holdings or manage personal finances without concerns of trading on material non-public information. The vesting of RSUs and options is a standard component of executive compensation in the biotechnology and pharmaceutical sectors, aligning management interests with long-term shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including Class B common stock convertible to Class A and long-term stock options with 48-month vesting schedules, is consistent with compensation practices seen in comparable early-to-mid-stage biotechnology companies.
• For instance, companies like Moderna (MRNA) or BioNTech (BNTX) in their earlier growth phases, or even larger established players like Amgen (AMGN) or Gilead Sciences (GILD) for their executives, often utilize similar multi-year vesting schedules to retain talent and incentivize long-term performance.
• The use of Rule 10b5-1 plans for sales is also a standard best practice for corporate insiders across all industries to manage personal liquidity while adhering to SEC regulations.

Related Party Transactions

• Indirect beneficial ownership of Class B Common Stock through LAHWRAN-3 LLC, LAHWRAN-4 LLC, and the Gibson Family Trust, where the Reporting Person has control or influence.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived negatively by some, but its execution under a 10b5-1 plan mitigates concerns about opportunistic selling. The continued vesting of equity compensation aligns the director's interests with long-term shareholder value.

Next Steps

• Continued vesting of various stock options for Christopher Gibson on a monthly basis.
• Potential future transactions by Christopher Gibson under the existing Rule 10b5-1 plan or new plans.

Key Dates

Recommendation

The filing details routine insider transactions, including a pre-planned sale and scheduled equity vesting. These events are typical for corporate directors managing personal finances and compensation and do not provide new material information to warrant a change in investment thesis. The company's fundamental prospects remain unchanged based on this Form 4.

Keywords

Recursion Pharmaceuticals, RXRX, Form 4, Insider Trading, Stock Sale, Director, Christopher Gibson, Rule 10b5-1, Restricted Stock Units, Stock Options, Beneficial Ownership